University of Texas MD Anderson: Novel Targeted Drug Induced Positive Response for Patients With Von Hippel-Lindau Disease-Associated Kidney Cancer
May 29, 2020
May 29, 2020
HOUSTON, Texas, May 29 -- The University of Texas's MD Anderson Cancer Center issued the following news release on May 28:
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC).
The results of the . . .
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC).
The results of the . . .